tiprankstipranks
BioMark Diagnostics (TSE:BUX)
CNQX:BUX

BioMark Diagnostics (BUX) Income Statement

3 Followers

BioMark Diagnostics Income Statement

Last quarter (Q3 2024), BioMark Diagnostics's total revenue was C$41.54K, an increase of 12.62% from the same quarter last year. In Q3, BioMark Diagnostics's net income was C$-406.76K. See BioMark Diagnostics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 23Mar 22Mar 21Mar 20Mar 19
Total Revenue
C$ 163.16KC$ 153.49KC$ 43.93KC$ 0.00C$ 263.28KC$ 0.00
Cost of Revenue
------
Gross Profit
C$ 163.16KC$ 153.49KC$ 43.93K---
Operating Expense
C$ 2.01MC$ 2.09MC$ 1.54MC$ 1.08MC$ 1.47MC$ 545.61K
Operating Income
C$ -1.85MC$ -1.93MC$ -1.50MC$ -1.08MC$ -1.21MC$ -545.61K
Net Non Operating Interest Income Expense
C$ -96.87KC$ -110.15KC$ -49.68KC$ -4.08KC$ -2.27KC$ 0.00
Other Income Expense
C$ -406.56KC$ -200.25KC$ -94.22KC$ -7.47KC$ -6.36K-
Pretax Income
C$ -1.54MC$ -1.84MC$ -1.45MC$ -1.09MC$ -1.22MC$ -545.61K
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
C$ -1.54M-C$ -1.45MC$ -1.09MC$ -1.22MC$ -545.61K
Basic EPS
C$ -0.07-C$ -0.02C$ -0.02C$ -0.02C$ -0.01
Diluted EPS
C$ -0.07-C$ -0.02C$ -0.02C$ -0.02C$ -0.01
Basic Average Shares
C$ 333.57M-C$ 77.93MC$ 73.30MC$ 71.30MC$ 65.91M
Diluted Average Shares
C$ 333.57M-C$ 77.93MC$ 73.30MC$ 71.30MC$ 65.91M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
C$ 474.11K--C$ 1.08MC$ 1.47MC$ 545.61K
Net Income From Continuing And Discontinued Operation
C$ -1.54M-C$ -1.45MC$ -1.09MC$ -1.22MC$ -545.61K
Normalized Income
C$ -1.13MC$ -1.35MC$ -1.07MC$ -1.09MC$ -1.21MC$ -545.61K
Interest Expense
---C$ 4.14KC$ 2.39K-
EBIT
C$ -1.44MC$ -1.73MC$ -1.40MC$ -1.09MC$ -1.21MC$ -545.61K
EBITDA
C$ -1.05MC$ -1.35MC$ -1.22MC$ -1.08MC$ -1.20MC$ -545.61K
Currency in CAD

BioMark Diagnostics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis